GO
Loading...

Worldwide Exchange

More

  • How to become a good leader     Wednesday, 14 May 2014 | 5:20 AM ET

    Ekaterina Walter, author of "Think Like Zuck", says Facebook's CEO, Mark Zuckerberg possesses the five traits of a very good leader, which include purpose and passion.

  • US market rally: How to invest     Wednesday, 14 May 2014 | 5:00 AM ET

    Michael Purves, chief global strategist at Weeden & Co., says the U.S. stock market rally should continue as blue chips should drag momentum stocks higher with them.

  • Formula E will make electric cars 'exciting': CEO     Wednesday, 14 May 2014 | 4:40 AM ET

    The electric car championship has secured funding and TV deals across the world ahead of its first season, says Alejandro Agag, CEO of Formula E Holdings.

  • UK economy slack falling at fast pace: Pro     Wednesday, 14 May 2014 | 4:30 AM ET

    Kiran Kowshik, currency strategist at BNP Paribas, discusses the U.K. economy following the release of the latest unemployment data.

  • Hardware electronics is 'trouble' for Sony: Pro     Wednesday, 14 May 2014 | 4:00 AM ET

    Pelham Smithers, head of Asian research at Pelham Smithers Associates, says Sony will remain in trouble until it can work out a way to "create an environment" to make its hardware electronics profitable.

  • GSK bribery investigation: Here's the latest     Wednesday, 14 May 2014 | 4:00 AM ET

    CNBC's Catherine Boyle comments on the latest developments in the GSK bribery investigation in China and on the second day of hearings for Pfizer and AstraZeneca's CEOs.

  • AstraZeneca can succeed on its own: CEO     Tuesday, 13 May 2014 | 7:30 AM ET

    Pascal Soriot, AstraZeneca CEO, says the group has what it takes to succeed on its own and that its "stand-alone strategy" will create value for its shareholders.

  • AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.

  • Pfizer suffering from patent cliff: Pro     Tuesday, 13 May 2014 | 5:50 AM ET

    Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.

  • Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.

  • Why you should favour large-caps     Tuesday, 13 May 2014 | 5:30 AM ET

    Andrew Burkly, head of institutional portfolio strategy at Oppenheimer & Co., says the underlying fundamentals for U.S. equities remain "pretty constructive", and large cap stocks should outperform small caps this year.

  • Gas shouldn't be used 'as a weapon': OMV CEO     Tuesday, 13 May 2014 | 5:10 AM ET

    Gerhard Roiss, CEO of OMV, discusses the impact of the Russian sanctions on European gas, and dismisses calls for a unified gas price across the region.

  • Pfizer 'aggressive' in cutting costs: Pro     Tuesday, 13 May 2014 | 5:00 AM ET

    Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.

  • 'Brand EU' not strong enough: Expert     Tuesday, 13 May 2014 | 4:40 AM ET

    Nicolas De Santis, president and secretary general at Gold Mercury International, says the European Union has an "identity problem" and needs a stronger brand and identity.

  • Sell in May and go away? Not for EM credit!     Tuesday, 13 May 2014 | 4:30 AM ET

    Christian Keller, head of emerging markets research at Barclays, says emerging market credit valuation is quite attractive but advises being "choosy and picky."

  • UK needs more 'long-termism': Opposition     Tuesday, 13 May 2014 | 4:00 AM ET

    Chuka Umunna, U.K. shadow business secretary, says the potential AstraZeneca takeover by Pfizer should be looked at as of national economic interest, and that more should be done to protect R&D jobs.

  • AstraZeneca takeover would be good for UK: Pro     Tuesday, 13 May 2014 | 4:00 AM ET

    Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.

  • Where to invest in equities     Monday, 12 May 2014 | 5:30 AM ET

    Mebane Faber, CIO of Cambria Investment Management, discusses where to get the best-value equities now there are a lot of "very cheap" countries.

  • EU won't recognize Ukrainian vote: Minister     Monday, 12 May 2014 | 5:14 AM ET

    The European Union will not recognize the "pseudo-referendum" in eastern Ukraine says Radoslaw Sikorski, Polish foreign minister, adding that it also refuses to recognize the annexation of Crimea.

  • Pfizer 'back on the attack'     Monday, 12 May 2014 | 5:05 AM ET

    Pfizer is "back on the attack" and trying to make sure the takeover of AstraZeneca is seen as being "all about science and medicine", CNBC's Catherine Boyle reports.

About Worldwide Exchange

  • CNBC's global business programme brings the business and investing world together. Each weekday Julia Chatterley considers the business stories that have global significance. With reports from CNBC's correspondents from around the world, Worldwide Exchange delivers essential, actionable information for any investor, anywhere who wants to be part of a global business conversation.

Contact Worldwide Exchange

  • Twitter: @CNBCWEX
  • Showtimes

    United States
    Monday - Friday 4a ET
    Europe
    Monday - Friday 10:00 CET
    Asia
    Monday - Friday 17:00 SIN/HK
    Australia
    Monday - Friday 20:00 SYD
    New Zealand
    Monday - Friday 22:00 NZ

 

  • Chatterley is CNBC’s European reporter covering key business and political events, as well as regular Eurogroup and EU leaders summits in Brussels.